Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 6/20 | 0.46 |
| ▸ | LATS2 | Q9NRM7 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 12/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14493287 | 0.90 | ALDH1A1 (0.47) | LATS1LATS2KDM4EALDH1A1HPGD | |
| SCHEMBL2842677 | 0.90 | KDM4E (0.47) | LATS1LATS2KDM4EALDH1A1HPGD | |
| SCHEMBL2834746 | 0.88 | PRKCI (0.47) | LATS1LATS2KDM4EALDH1A1HPGD | |
| SCHEMBL2833848 | 0.82 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL2841965 | 0.82 | HPGD (0.40) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL2838859 | 0.81 | ALDH1A1 (0.39) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL14493231 | 0.81 | KDM4E (0.43) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL2838134 | 0.80 | KDM4E (0.38) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL2835617 | 0.79 | ALDH1A1 (0.58) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL2840705 | 0.79 | ALDH1A1 (0.47) | LATS1LATS2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662814-B2 | 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-02-16 | — | — | US | claimed |
| CN-100582112-C | 4-aminothieno [2,3-d] pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors | ALMIRALL PRODESFARMA SA | 2010-01-20 | — | — | CN | claimed |
| EP-1590352-B1 | 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL LAB (ES) | 2007-06-27 | — | — | EP | claimed |
| US-20060229306-A1 | 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-10-12 | — | — | US | claimed |
| CN-1761671-A | 4-aminothieno [2,3-d] pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors | ALMIRALL PRODESFARMA SA (ES) | 2006-04-19 | — | — | CN | claimed |
| EP-1590352-A1 | 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-11-02 | — | — | EP | claimed |
| WO-2004065391-A1 | 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-05 | — | — | WO | claimed |
| US-7662814-B2 | 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-02-16 | — | — | US | disclosed |
| US-7662814-B2 | 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-02-16 | — | — | US | disclosed |
| CN-100582112-C | 4-aminothieno [2,3-d] pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors | ALMIRALL PRODESFARMA SA | 2010-01-20 | — | — | CN | disclosed |
| EP-1590352-B1 | 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL LAB (ES) | 2007-06-27 | — | — | EP | disclosed |
| EP-1781655-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060229306-A1 | 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-10-12 | — | — | US | disclosed |
| CN-1761671-A | 4-aminothieno [2,3-d] pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors | ALMIRALL PRODESFARMA SA (ES) | 2006-04-19 | — | — | CN | disclosed |
| WO-2006018727-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1590352-A1 | 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065391-A1 | 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004065391-A1 | 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229306-A1 | 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors | PDE7B, PDE7A, PDE3A | LATS1 4317/4885LATS2 4054/4885KDM4E 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.